Bionano Genomics, Inc.
BNGO · Price history
Price at last available close
$1.21
−$0.47 (-28.27%) 1M
2026-10-28
Tap or drag sideways to inspect a price. Use two fingers to compare automatically. Release to scroll. Use Shift + arrow keys to compare with a keyboard.
Company & revenue
About Bionano Genomics, Inc.
Primary reporting period: 2025-12-31 · Research updated Oct 13, 2026. A research update is not a new financial filing.
Who they are
Bionano Genomics, Inc. focuses on providing advanced solutions for analyzing genomes. The company's flagship offering is Saphyr, a complete system that processes samples to results, enabling the analysis of structural variations in the genome using optical genome mapping. This technology is vital for deciphering genetic variations and their functional roles.
How they make money
Bionano Genomics generates revenue primarily through the sale of optical genome mapping (OGM) instruments, consumables, and software solutions to research and clinical institutions. Additionally, the company earns service revenue by providing OGM-based diagnostic testing services through its Bionano Laboratories business.
Products & services
Optical genome mapping (OGM) systems, genome analysis software, nucleic acid extraction and purification solutions using isotachophoresis (ITP) technology, and OGM-based diagnostic testing services.
Brands & revenue mix
Business unit providing OGM-based diagnostic testing services.
Separate brand revenue is not available in this research.Source
Revenue share is not unit sales or a best-seller ranking. Parent brands and included sub-brands can overlap; do not add overlapping rows.
Product / operating segments
No reconciled product or operating-segment revenue breakdown is available for the current research period. Company-wide revenue remains separate from segment disclosure.
Geographic revenue
Period ended 2025-12-31Source
Period ended 2025-12-31Source
Period ended 2025-12-31Source
Calculated from reported segment revenue. Check the source period and revenue basis before comparing shares. Categories can overlap and may not add to 100%.
Customer types
Customer concentration
The company has historically disclosed that it does not have significant customer concentration, though it monitors reliance on specific distributors and clinical partners.
Suppliers, materials & equipment
- Contract manufacturing and component suppliers — The company relies on third-party contract manufacturers and suppliers for the production of its instruments and consumables; specific supplier names are not disclosed.Source
Competitors
- Illumina, Inc. — Competes in the broader genome sequencing and analysis market.Source
- Pacific Biosciences of California, Inc. — Competes in long-read sequencing and structural variation analysis.Source
- Oxford Nanopore Technologies — Competes in long-read sequencing and structural variation analysis.Source
Strengths
Sources
Wall Street Score
Overall investment score · Quality, value, risk and opportunity
10
Poor
View category scores →
Company Quality
How good is the actual business—regardless of today’s stock price?
25
Poor
Financial Strength
64
Business Quality / Moat
0
Management
0
Growth Quality
34
Risk / Durability
5
Uses financial strength, moat, management, growth quality and durability. It excludes share price, P/E, market cap, intrinsic value and margin of safety.
Opportunity
Opportunity Score · How does the current price compare with estimated value?
41
Avoid
Based on current valuation, company quality, recent trends, and available market signals.
View score details →
Model Outlook
12-month model · What does the model think happens next?
43/100
Building Historical Record
Model Score 43/100 — estimates relative performance potential, distinct from the overall Wall Street Score and the separate Company Quality score.
Probability unavailable — the model has not produced a calibrated probability yet.
Click for full breakdown →
WSS View
The quick read
The overall Wall Street Score is low across its combined quality, valuation and risk inputs. This can reflect an expensive share price, business weaknesses, or both; check Company Quality and the category breakdown before drawing a conclusion.
At today’s price, the WSS valuation framework currently reads as less attractive based on the available valuation and market data.
The model outlook is currently cautious.
- •Balance-sheet / debt profile scores strongly
- •Insider activity signal is favorable
- •Share split detected
- •Material dilution — approximately 110.7% share-count growth
- •MAJOR RED FLAG: Reverse split proposed / authorized
- •CRITICAL: Going-concern warning
- •CRITICAL: Bankruptcy / liquidation risk
Company-specific research
Questions worth answering for BNGO
These questions are generated from this company's current financial and score data so the page adds context instead of treating the headline score as a stand-alone conclusion.
- •Can BNGO maintain its current revenue growth rate and improve the amount of that revenue that turns into earnings and cash?
- •How long can BNGO fund negative free cash flow using its current cash position before it may need more debt or new shares?
- •Does BNGO's balance between cash and debt leave enough flexibility if business conditions weaken?
- •What specifically needs to improve for BNGO to reach sustainable profitability?
- •What future growth or profitability would be needed to justify BNGO's current valuation?
Essential Investment Snapshot
Wall Street Score
10
Opportunity Score
41
Market Cap
$14.2M
P/E Ratio
-0.4
EPS
$-3.73
52-Week High
$5.50
52-Week Low
$1.00
Beta
1.65
Analyst Target
$5.00
Shares Outstanding
11.5M
Total Revenue
$30.2M
Total Debt
$6.7M
Dividend
No current dividend
Liquidation Value / Share
$2.75
Momentum & Volatility Signals
Two different market-behavior signals. Momentum measures direction and trend strength. Volatility measures how large and unstable the price moves are, regardless of direction.
Strong downward momentum
Normal movement
A high momentum score means price has been trending upward with confirming short- and medium-term strength. A low score means downward or weakening momentum.
A high volatility score means larger, less stable price swings. It can happen while a stock is rising or falling, so high volatility is not automatically bullish or bearish.
Important: the volatility score above is based on realized price volatility. Implied volatility (IV) comes from options prices and represents the market's expected future movement. Wall Street Score will keep IV separate and will only display it when a verified options-chain feed is available.
Notices for BNGO
Detected from reported data — verify before acting.Share split detected
A recent SEC filing references a reverse stock split/share consolidation. Repeated reverse splits receive progressively harsher score ceilings.
Supporting sourceMaterial dilution — approximately 110.7% share-count growth
Shares outstanding increased approximately 110.7% across stored score snapshots. This is material dilution and is applying a Wall Street Score ceiling of 35.
MAJOR RED FLAG: Reverse split proposed / authorized
A recent SEC filing discusses authorization, approval, or a proposal for a reverse stock split. This is treated as a major distress/listing-risk signal and caps Wall Street Score below 30 while pending.
Supporting filingCRITICAL: Going-concern warning
A recent SEC filing contains explicit going-concern language. Wall Street Score is capped at 15 until the distress condition is resolved in later filings.
Supporting filingCRITICAL: Bankruptcy / liquidation risk
A recent SEC filing contains bankruptcy/liquidation language. Wall Street Score is capped at 10.
Supporting filingDebt service risk
Interest coverage is low (~-111.9x). Earnings may be strained to cover interest expense.
Community Sentiment
0 active · 0 total callsNo personal call yet on BNGO.
Potential upside factors
- +Growth opportunities may come from revenue expansion, margin improvement, new products, market-share gains, and stronger cash flow.
- +Proprietary optical genome mapping (OGM) technology platform.
- +Integrated portfolio of instruments, software, and diagnostic services.
Potential downside factors
- −Key risks may include competition, margin pressure, debt levels, valuation risk, and changes in demand within the Medical - Instruments & Supplies industry.
- −History of operating losses and potential need for additional capital.
- −Dependence on market adoption of OGM technology.
- −Risks associated with third-party manufacturing and supply chain.
These research factors come from saved company research and financial data, not community votes. They are starting points to verify against filings, not buy or sell recommendations.
Create a free account to make a call.
Scores
Click any score for full breakdownWas this stock page easy to understand?
One click helps us improve the research experience. This is not tied to an investment decision.
Score Changes
5 historical score records availablePrevious Score
21
Sep 9, 2026
Change
-11.4
points
Current Score
10
Oct 1, 2026
Category Changes
BNGO decreased 11.4 points because Revenue declined by 3.2 points.
Negative Contributors
- − Revenue declined by 3.2 points
Projected Score
Projected Score
13
Projected Change
+3.4 points
Preliminary comparable-period financial changes suggest improvement of approximately 3.4 points. This is a projected estimate, not the official WallStreetScore.
Price vs. Value
Valuation unavailableCurrent Price
$1.21
Model Intrinsic Value
—
Difference
—
Margin of Safety
—
Intrinsic value is not currently available for this stock, so valuation can't be calculated.
Financial Charts
Revenue
Additional Metrics
Operating Cash Flow
Total Debt
Total Assets
Net Margin %
Free includes 3 annual periods plus available TTM; Premium includes up to 10 annual periods. History depends on available company filings. Swipe the table horizontally to see older periods. A dash means unavailable, not zero.
| Line Item | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $30.2M | $28.5M | $30.8M | $36.1M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Cost of Revenue | $15.8M | $22.3M | $30.4M | $26.6M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Gross Profit | $14.3M | $6.3M | $380K | $9.6M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Research & Development | $12.2M | $11.4M | $24.8M | $54.0M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| SG&A Expenses | $34.3M | $28.2M | $51.9M | $95.0M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Operating Expenses | $46.5M | $39.6M | $104.4M | $224.8M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| EBITDA | -$22.4M | -$16.3M | -$97.5M | -$213.6M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Operating Income | -$32.2M | -$33.3M | -$104.0M | -$215.2M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Interest Expense | $213K | $298K | $289K | $5.1M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Income Before Tax | -$32.1M | -$26.3M | -$112.0M | -$232.4M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Income Tax Expense | $66K | $67K | $33K | $62K | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Net Income | -$32.2M | -$26.4M | -$112.0M | -$232.5M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Basic EPS | $-3.73 | $-4.85 | $-88.13 | $-408.48 | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Basic Shares | 11.55M | 5.45M | 1.27M | 569K | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Diluted Shares | 11.55M | 5.45M | 1.27M | 569K | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
Earnings Summary
Revenue
$8.2M
Estimate unavailable.
Revenue Beat/Miss
Not available (no estimate stored)
EPS
-$0.64
Estimate unavailable.
EPS Beat/Miss
Not available (no estimate stored)
Debt Change
-65.8%
Cash Change
+4.7%
Margin Change
+11.0 pp
Debt and cash show percentage changes versus the comparison period; margin shows the change in percentage points (pp). These are company-wide changes, not per-share amounts.
Financial Changes Since Prior Period
What Improved
- Margins expanded
- Cash position grew
- Debt reduced
Potential Score Impact
Positive indicators included revenue growth, cash levels, debt levels, net income margin. Pressure indicators included EPS growth. These factors may support or pressure the Revenue, Management, Financial, and Debt categories; this summary does not claim that the stored scores changed.
Stored Earnings Analysis
Revenue increased 21.4%. EPS declined 67.8%. Cash increased 4.7%. Total debt declined 65.8%. Net income margin improved by 11.0 percentage points.
Earnings-Call Transcript
Earnings-call transcript analysis is not currently available.
These results may influence future scores when the next evaluation is completed.
Insider Activity
Guru / Smart Money
Guru Score
Smart Money
Number of Gurus
Total Guru Value
Avg Portfolio Weight
Largest Holder
Largest Holder %
New Positions
Increased Positions
Reduced Positions
Exited Positions
Net Guru Sentiment
Short Interest
Dividend History
Dividend data is not available yet. Missing data does not mean this company pays no dividend.
Conservative Projected Values
3 Years
$———.——
5 Years
$———.——
10 Years
$———.——
Conservative Projection Rate
——%
Conservative Projected Values — price projections derived from actual 10-year adjusted historical returns, conservatively adjusted and capped at 8% annually. These are distinct from the Outperformance Model Score and WallStreetScore.
Conservative Projected Values
Premium unlocks the 3-year, 5-year, and 10-year conservative projected values with full calculation breakdowns based on actual historical returns.
Start 7-Day Free TrialHistorical Outperformance Record
Premium includes stored forecasts and any available evaluated results. Completed results, win rates and calibrated probabilities are shown only when supported records exist; access does not create historical outcomes.
Start 7-Day Free TrialHistorical Trends
5 historical recordsHistorical Score Chart
3 of 5 records shownWall Street Score
Debt Score
Revenue Score
Asset Score
Capital Score
Management Score
Moat Score
Valuation Score
Buffett Score
Intrinsic Value
Value Reference
Margin of Safety %
Related Companies
Medical - Instruments & SuppliesNews
Bionano Laboratories Announces Expansion of Diagnostic Testing Based on Optical Genome Mapping for Hematologic Malignancies
Bionano Announces Three New Peer-Reviewed Studies Demonstrate Clinical Value of Bionano's Optical Genome Mapping Across Myelodysplastic Syndromes and Acute Myeloid Leukemia
Bionano Laboratories Announces Proposed Local Coverage Determination (LCD) from MolDX for Genome-Wide Detection of Structural Variants in Hematologic Neoplasms
Bionano Laboratories Announces New York State Department of Health Approval of Lab Developed Tests Based on Optical Genome Mapping
Rumor Mill · BNGO
Corporate developments & opportunities
No reviewed developments match this filter.
Evidence credibility is not a forecast of stock performance. Rumor Mill is separate from the WSS score.
Related Stock Research
Continue researching this company with related Wall Street Score rankings and investing guides.
Score Alerts
Premium unlocks alerts when a score rises, falls, or reaches your target price.
Start 7-Day Free TrialPortfolio Score
Premium unlocks portfolio scoring, strongest and weakest holdings, and overall margin of safety.
Start 7-Day Free Trial